2015
Adherence and HIV RNA Suppression in the Current Era of Highly Active Antiretroviral Therapy
Viswanathan S, Justice AC, Alexander GC, Brown TT, Gandhi NR, McNicholl IR, Rimland D, Rodriguez-Barradas MC, Jacobson LP. Adherence and HIV RNA Suppression in the Current Era of Highly Active Antiretroviral Therapy. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2015, 69: 493-498. PMID: 25886923, PMCID: PMC4482798, DOI: 10.1097/qai.0000000000000643.Peer-Reviewed Original ResearchConceptsHIV RNA suppressionOdds of suppressionActive antiretroviral therapyRNA suppressionHAART regimenAntiretroviral therapyVeterans Aging Cohort Study Virtual CohortHighly active antiretroviral therapyFirst HAART regimenProtease inhibitor usersRepeated-measures logistic regressionVeterans' Affairs pharmacyViral load suppressionHAART usersNew HAARTRegimen typeInhibitor usersHIV infectionNonnucleoside reverseLow adherenceAdherence levelsPerfect adherenceVirtual cohortLogistic regressionDuration of time
2009
HIV infection in the elderly
Gebo KA, Justice A. HIV infection in the elderly. Current Infectious Disease Reports 2009, 11: 246-254. PMID: 19366568, PMCID: PMC3129647, DOI: 10.1007/s11908-009-0036-0.Peer-Reviewed Original ResearchOlder patientsYounger patientsBetter virologic suppressionOlder HIV patientsActive antiretroviral therapyManagement of HIVPrevalence of HIVDrug-drug interactionsAntiretroviral regimenHAART initiationHAART regimenVirologic suppressionAntiretroviral therapyHIV patientsImmunologic benefitsHIV infectionPatientsSide effectsHIVPopulation agesRegimenAgeHAARTComorbiditiesTherapy
2004
A Pilot Study of Once-Daily Antiretroviral Therapy Integrated With Tuberculosis Directly Observed Therapy in a Resource-Limited Setting
Jack C, Lalloo U, Karim QA, Karim SA, El-Sadr W, Cassol S, Friedland G. A Pilot Study of Once-Daily Antiretroviral Therapy Integrated With Tuberculosis Directly Observed Therapy in a Resource-Limited Setting. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2004, 36: 929-934. PMID: 15220699, DOI: 10.1097/00126334-200408010-00006.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAdolescentAdultAlkynesAntibiotics, AntitubercularAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveBenzoxazinesCosts and Cost AnalysisCyclopropanesDidanosineDrug Therapy, CombinationFemaleHIV InfectionsHumansLamivudineMaleMiddle AgedOutpatient Clinics, HospitalOxazinesPilot ProjectsSouth AfricaTreatment OutcomeTuberculosisUrban PopulationConceptsAntiretroviral therapyTB therapyViral loadPilot studyTwenty HIV-positive patientsSmear-positive pulmonary TBCD4 count increaseDrug-sensitive TBObserved therapy programStandard TB therapyActive antiretroviral therapyHIV-positive patientsMean CD4 countMean viral loadCells/Resource limited settingsResource-limited settingsDaily didanosineHAART regimenCD4 countHIV clinicPulmonary TBTB clinicNeurologic toxicityObserved therapy
2001
Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users
Celentano D, Galai N, Sethi A, Shah N, Strathdee S, Vlahov D, Gallant J. Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users. AIDS 2001, 15: 1707-1715. PMID: 11546947, DOI: 10.1097/00002030-200109070-00015.Peer-Reviewed Original ResearchConceptsInjection drug usersActive antiretroviral therapyAntiretroviral therapyDrug usersCell countLow health care accessNon-HAART regimensAntiretroviral therapy useDual combination therapyProportional hazards regressionMain outcome measuresMore treatment optionsHealth care accessNon-drug usersHAART regimenLow CD4HAART useHIV careCohort studyStudy clinicTherapy useSelf-reported initiationHazards regressionMethadone treatmentTreatment eligibility
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply